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Abstract
The inherited prion diseases (IPD) are a group of untreatable neurodegenerative diseases which 
segregate as autosomal dominant traits. Mutations in the prion protein gene (PRNP) were first 
found to be causal of IPD in 1989, prior to the molecular genetic characterisation of any other 
neurodegenerative disease. Predictive testing for IPD has subsequently been carried out at a single 
UK clinical and research centre for 22 years. We have analysed the uptake, consequences and 
factors influencing the decision for predictive testing over this period. 104 predictive tests were 
done on individuals at 50% risk, compared with 135 positive diagnostic tests. Using genealogies 
from clinical records we estimated that 23% of those at 50% risk have completed testing. There 
was no gender bias, and unsurprisingly, there was a slight excess of normal results because some 
patients were already partly through the risk period because of their age. An unexpectedly large 
number of patients developed symptoms shortly after predictive testing, suggesting that 
undisclosed early symptoms of disease may prompt some patients to come forward for predictive 
testing. 15% of predictive tests were done more than 10 years after molecular diagnosis in a 
proband. A strong determinant of the timing of testing in these patients was a second diagnosis in 
the family. IPD may generate infectious prions which might be transmitted by surgical procedures, 
however we found no evidence that public health information influenced decisions about 
predictive testing.
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Introduction
Prion diseases are a group of fatal and transmissible neurodegenerative diseases of humans 
and animals. Fundamental to the pathogenesis of these disorders is the autocatalytic 
conversion of the normal cell surface prion protein (PrPC) to a multimeric conformer (PrPSc) 
and consequent neuronal toxicity. About 10-15% of prion disease is familial, all of which 
can be explained by mutation in the coding region of the prion protein gene (PRNP), either 
as missense mutations leading to amino acid substitutions, truncating mutations leading to 
premature stop codons, or alteration in the number of an octapeptide repeat moiety in the N-
terminal domain 1-3.
A range of clinical syndromes comprise IPD, including the rapidly progressive myoclonic 
dementia Creutzfeldt-Jakob disease (CJD), and more slowly progressive ataxic and 
cognitive syndromes such as Gerstmann-Straussler-Scheinker (GSS). The age of clinical 
onset in IPD varies according to the mutation in the prion gene. Some mutations towards the 
C-terminal of the gene (e.g. p.E200K) have a typical onset in late middle age. Other 
mutations (e.g. 6-octapeptide repeat insertional mutation, 6-OPRI) can have a strikingly 
early onset in the third decade of life4. The normal repeat region of PRNP contains 4 or 5 
copies of an octapeptide motif. Disease associated insertional mutations are stable between 
generations and have more than three extra repeats. An inverse correlation between length 
and mean age of onset has been reported5. Different phenotypes can occur in association 
with the same mutation and among family members. Most of the mutations appear to be 
fully penetrant; families with the p.E200K, p.D178N and 4-OPRI mutations however have 
provided examples of elderly unaffected gene carriers who appear to have escaped the 
disease 2, 5.
The NHS National Prion Clinic (NPC) based at the National Hospital for Neurology and 
Neurosurgery provides a tertiary referral service for patients with or at risk of developing 
prion disease in the UK. It is notified of all suspect prion disease patients in the UK and 
coordinates its work closely with the National CJD Research and Surveillance Unit in 
Edinburgh. The NPC, and its predecessor specialist clinic at St Mary’s Hospital, London, 
has been the only specialist NHS centre for prion disease predictive testing since 1990. The 
experience of prion disease in the early years informed the subsequent development of 
predictive testing guidelines for Huntington’s Disease (HD) from 1993 6. This long term 
experience has allowed a close clinical relationship to develop with large extended pedigrees 
of 6-OPRI and p.P102L IPD 7, 8.
This paper describes the experience of predictive testing for IPD by studying a cohort of 
families identified in the UK from 1990 until the end of 2011. Whilst less common than 
many other genetic disorders, the historically early identification of the prion protein gene, 
the comprehensive referral patterns and single centre in the UK and the public health 
implications of prion disease diagnosis offer an opportunity for distinct insights into the 
factors that determine the uptake and consequences of predictive testing.
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Methods
The family cohort was identified through probands with a molecular diagnosis of IPD in the 
UK from 1990 to October 2011 (n=135). This was facilitated by a sample database which 
has been continuously maintained and records all molecular tests since 1990 at the MRC 
Prion Unit and predecessor organisations. Clinical files were sought for all these individuals. 
17 diagnostic tests were excluded because minimal associated genealogical information was 
found. 14/17 excluded diagnostic tests were from the 1990 – 1997 period. Pedigrees were 
constructed using information from clinical notes allowing individuals at risk of IPD to be 
identified. Only 1st degree relatives were included for the purposes of this study (living 
parents when neither were symptomatic, unaffected siblings and adult offspring). In IPD 
there are several examples of a child becoming symptomatic before a parent 9.
In counselling for IPD the Public Health England (formerly the Health Protection Agency) 
requests that physicians inform families about the potential to transmit prions by invasive 
surgical or dental procedures. For the purposes of this study we assume that communication 
of genetic risk and the public health requirements are universal. Individuals presenting for 
predictive testing were calculated in a similar way using the MRC Prion Unit database from 
1990 until the end of 2011. The first predictive test for an individual living in the UK was 
carried out in September 1991. 8 individuals who had predictive testing and were at 25% 
risk or less were excluded. Two families, both with a p.E200K mutation, were excluded 
because feedback of the genetic test result in the proband did not occur. The HD genetic 
counselling protocol recommends a cooling-off period of at least 1 month between the initial 
visit and the blood sample being taken. Three individuals fell into this category at the start of 
the project and were not included in the numbers eligible for predictive testing.
Clinical and molecular genetic research studies at the MRC Prion Unit and NHS NPC have 
been approved by the local Research Ethics Committee.
Statistics were done using the IBM SPSS Statistics package and Excel (Microsoft Inc.). We 
used a permutation/simulation strategy to address questions about whether the observed 
proportion of abnormal predictive tests was within a range compatible with chance alone. In 
doing so we assumed a liability curve based on a normal distribution of age at clinical onset, 
for those mutations in which this was known with confidence, with mean and standard 
deviations of onsets in years as follows, 6-OPRI 35 +/− 7, p.P102L 51 +/− 9, p.D178N 49 +/
− 11, p.E200K 58 +/− 9 2. Estimated prior probabilities of being a mutation carrier were 
calculated for each individual using their age, and the mean and standard deviation of onset 
for the specific mutation. This was done with the cumulative NORM.DIST function of 
Excel. We then simulated mutation discovery in samples of 87 patients based on their prior 
probabilities of being mutation carriers on 163780 occasions using random number 
generation in Excel. Thus we generated a chance expectation of mutation discovery in the 
sample which allows for the prior risk for each individual in our sample based on their 
mutation and age. Estimation of the probability of clinical presentation in the year following 
testing was calculated by subtraction of the prior probabilities of being a mutation carrier at 
age at testing from that at age + 12 months. Simulation was done in a similar way based on 
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the calculated probabilities of each individual’s presentation with disease in a 12 month 
period.
Results
Predictive testing has been carried out on 104 individuals (23% of the 460 eligible at risk 
individuals) in the UK over the 22 year period to the end of 2011. Additionally 135 
diagnostic tests were carried out (table 1). Between 1990-2011 there has been an increase in 
uptake of predictive testing (figure 1). Although this may represent an increasing trend, 
particularly from around the year 2000, (Pearson correlation for annual number of predictive 
tests 1990-2011 versus duration since 1990: P<0.001), it is also possible that the predictive 
test number may have plateaued since 2005, with the annual number of tests between 
2005-11 fluctuating around an average of 11/year (range 9-14). However, there was a 
similar trend in abnormal diagnostic tests (Pearson correlation for annual number of 
diagnostic tests 1990-2011 versus duration since 1990: P=0.01), which also may have 
plateaued between 2005-11 (average 10/yr, range 4-17). New diagnosis of IPD might cause 
an increase in predictive tests as more individuals become aware of their risk status and 
promptly seek testing. When this was taken into account in regression analysis there was no 
statistically significant independent linear trend in predictive tests (P=0.25). The IPD 
mutations most commonly tested were 6-OPRI, p.P102L and p.E200K (table 1). There were 
no significant differences in rates of uptake of predictive testing between different 
mutations.
From the 104 predictive tests 42 were abnormal (62 normal, no indeterminate findings). 
Although this proportion is marginally statistically significant compared with an expectation 
of 50% abnormal (P=0.03, binomial test), this analysis does not take into account the fact 
that individuals present for predictive testing having lived through part of the risk period. 
For 4 of the most common mutations (6-OPRI, p.P102L, p.D178N, p.E200K) we modelled 
the true prior probability of being a mutation carrier based on the known liability curves for 
these mutations. We estimated the proportion of the risk period survived by each individual 
using mean age of onset and standard deviation from the published literature (see methods). 
35 mutations were found in 87 individuals in this subset of mutation types, whereas 30 
would be most likely (95% confidence interval 23-37, based on 163780 permutations).
Age at predictive testing varied from 18-90, most commonly in the fourth decade of life 
(figure 2). The mean age for predictive testing across the mutations is 39.78 years 
(SD=14.58). The age distribution was distinct between different mutations (P=0.01, one-way 
ANOVA), driven by a much older age at testing for the p.E200K mutation vs. the 6-OPRI 
mutation (P<0.001, Tukey post hoc test), consistent with the differences in age of clinical 
onset in these mutations. Predictive testing was similarly frequent in men and women (table 
2, P=0.18).
We went on to consider other factors that might determine the timing of predictive testing. 
Sixty per cent of individuals were tested within 2 years of the proband’s molecular diagnosis 
(figure 3). Of those who came forward for predictive testing more than 10 years after 
becoming aware of their risk, 8/16 had a further relative who had either predictive or 
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diagnostic testing in the previous 2 years. Of these 16 individuals 3 were younger than age 
18 when they became aware of their risk and were not eligible for predictive testing at that 
time according to current UK practice. The timing in relation to the decision to have 
children was not addressed in this study.
We also considered whether social factors or comprehension might influence testing, 
perhaps because of better access to healthcare. Higher proportions who were parents, a 
predominance of individuals living as a couple, and an overrepresentation of those in the 
higher socio-economic brackets has been observed in predictive testing for other 
neurodegenerative conditions10-12. From 42 individuals who came forward for predictive 
testing and had an abnormal test result, twenty are enrolled in an observational cohort study 
National Prion Monitoring Cohort (NPMC) of prion disease which involves longitudinal 
neuropsychological assessments. The mean IQ for these individuals was 96.6 (SD=11.8) 
suggesting no strong association between intelligence and predictive testing.
We further considered the possibility that individuals were privately concerned about 
disease onset because of mild or transient symptoms, and presented for predictive testing to 
resolve diagnostic issues. From 42 individuals with a positive gene result, 10 became 
symptomatic in the study period, notably, 7/10 became symptomatic within 12 months of 
predictive testing, more than would be expected by chance (P<0.0001, permutation testing 
see methods). These data suggest that proximity to clinical onset is strongly associated with 
requests for predictive testing.
The proportion of abnormal predictive tests for the 6-OPRI mutation was low (7 patients 
from 25 tests, p=0.02 vs 50% expectation), particularly so when three individuals who 
became symptomatic within 12 months were excluded (4 patients, p=0.002 vs 50% 
expectation). This finding might be explained by the presence of a premorbid personality 
disorder in some gene mutation carriers that influences the decision to present for predictive 
testing, however, permutation testing did not show that the proportion of positive results in 
6-OPRI were different from chance expectation when taking into account the liability curve 
for this mutation (P=0.12).
Finally we considered some of the consequences of living with the risk of IPD. The NPC is 
aware of two individuals (50% at-risk) who were aware of IPD risk and committed suicide. 
They had not come forward for predictive testing and it is unknown if they had early 
symptoms at the time. No asymptomatic individuals who had requested predictive testing 
have attempted suicide as far as the NPC is aware. A recent study of behavioural and 
psychiatric symptoms in participants in the MRC Prion Unit’s NPMC study included 24 
individuals at risk of inherited prion disease (14 mutation carriers and 10 untested first 
degree relatives). Current depressive symptoms were reported in at least one assessment by 
6 of these individuals (25%). Although this is a small group from which to draw 
conclusions, this is above the expected prevalence in the general UK population 13, is 
similar to that reported in studies of presymptomatic Huntington’s disease 14, and it is 
certainly our clinical experience that the knowledge of being at risk can have a significant 
psychological impact in some individuals.
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Discussion
We have analysed the uptake, consequences and factors influencing the decision for 
predictive testing over a 22 year period at a single national centre. Overall the uptake of 
predictive testing in IPD is high (23%) when compared to typical uptake of predictive 
testing for HD which ranges from 3-24% in similar studies 11, 15-22. The uptake of 
diagnostic and predictive testing for IPD (figure 1) increased over the first 16 years of 
testing, but the data suggests that this may then have reached a plateau, with levels of testing 
in the subsequent 6 years fluctuating around an average. In comparison, in HD, a decline in 
the uptake of testing has been observed 22, 23. There are several factors which may have 
influenced these trends.
First in HD a suggested explanation for driving trends is expectation about experimental 
therapies 22. In IPD, increasing uptake is associated with increased ascertainment and 
diagnosis of symptomatic patients and an increase in clinical trial-like research at the MRC 
Prion Unit since the PRION-1 trial (2001-2007) which involved biannual information days. 
Twenty individuals who have had predictive testing are enrolled in the on-going NPMC 
Study. The opportunity to contribute to efforts towards the development of treatments is a 
motivating factor for some patients. A significant difference with other inherited 
neurodegenerative diseases is that patients with IPD may generate infectious prions that 
potentially can be transmitted by invasive medical procedures. The NPC therefore delivers a 
public health message to the family when a proband is diagnosed. We found no evidence 
that this information influenced decisions for predictive testing; however it is conceivable 
that this message was a prompt to encourage sharing of genetic information in families.
Secondly, initially in HD there was a relatively high uptake of predictive testing which then 
declined after four years and has fluctuated at a lower level since. When a test first becomes 
available there will be a backlog of people who are asymptomatic who wish to be tested 
whereas after this group has been tested there will be a fixed, and lower, number of 
asymptomatic patients accrued each year. In the case of prion diseases the situation is more 
complex as there are multiple, rather than a single, mutations and these were discovered 
over a period of years. This would have the effect of offsetting the backlog effect at least for 
many years. If correct, one would predict a gradual lowering of the number of asymptomatic 
patients coming forward now that all of the common mutations are known.
Several factors may influence the proportion of abnormal predictive tests. Excess normal 
results have also been observed in HD studies of individuals at 50% risk 22, 24. Similarly in 
the current study the proportion of patients with normal results was greater than half (62 vs 
42). However this analysis is flawed as it assumes that the population studied is the same 
throughout the entire lifetime of that group. In fact the number of people who become 
symptomatic with age increases and these individuals who would have tested positive in the 
asymptomatic period, are removed from the at risk population so that the chances of getting 
a positive presymptomatic test decreases. We have overcome this problem by correcting for 
the risk period. Furthermore, the calculation is probably confounded by the fact some of 
those tested near to the likely onset of symptoms are thought by the clinician to be 
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symptomatic a situation that certainly occurs in prion disease. After considering these issues 
we have shown that the IPD results are no different from chance expectation.
The majority of patients asked for predictive testing within 2 years of diagnosis in the 
proband. In HD it has been observed that 32.4% of candidates presented for testing within 1 
year of becoming aware of their risk 25. Half of those who wait more than 10 years before 
predictive testing for IPD had a second relative who had recently presented for predictive or 
diagnostic testing. These data suggest that the major drive for predictive testing is personal 
exposure to the disease, prompting individuals to think further about their own risk. In 
studies of other inherited conditions, anxiety reduction, family planning and to inform their 
children are common reasons for genetic testing 26-28. Although we were not able to assess 
objectively these aspects, where this information has been recorded in patient notes, similar 
reasons were documented.
Although suicide rates are increased in patients with HD this has not been found in 
presymptomatic patients having predictive testing 11, 29, 30. The decline of adverse events 
over time is a common occurrence in predictive testing programs 31, 32. Our protocol is 
always to involve local Clinical Geneticists in predictive testing, and to date we are not 
aware of any suicides or attempts in patients who have had predictive testing. Nevertheless, 
psychiatric morbidity is prevalent, particularly mild-moderate mood disorder, emphasising 
the need for long term follow-up and support.
We noted a low proportion of positive predictive tests with the 6-OPRI IPD mutation 
however this was not statistically significant and further studies are required. Clinical 
assessment of patients from the large British kindred affected by 6-OPRI led to the 
observation that patients carrying the mutation were often reported to have abnormal, 
antisocial personality traits from a very young age, pre-dating the onset of the classical 
neurological or cognitive symptoms of the disease by many years 4, 33. Interestingly this has 
also been reported in a small number of patients with different OPRI mutations 34, 35. 
Whether this effect is due to the mutation per se or to environmental factors is unclear. We 
have made efforts to address this intriguing issue with prospective assessment of at risk 
individuals using personality assessment and neuropsychological tools, but have so far been 
unable to engage sufficient numbers of these individuals with this research to allow 
meaningful conclusions to be drawn.
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Figure 1. 
The number of predictive (positive and negative results) and diagnostic tests (only positive 
results) in the UK since the discovery of causal mutations for prion disease in 1989.
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Figure 2. Requests for predictive testing vary by age and mutation type
Much of this variation can be explained by the expected age at clinical onset of each 
mutation.
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Figure 3. 
Duration between diagnosis in a proband and referral for predictive testing. Many of the late 
referrals can be explained by proximity to a second diagnosis in the family. Parentheses 
indicate number of individuals who were under the age of 18 when they were made aware of 
risk. (U = unknown).
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Table 1
Predictive tests done as a proportion of eligible first degree relatives (at 50% risk), for each PRNP gene 
mutation.
Mutation Number of
diagnostic tests
Number of first
degree relatives
at-risk
Number of predictive
tests performed (% of
eligible first degree
relatives)
G54S 1 2 0 (0)
4OPRI 4 9 1(11)
5OPRI 9 20 3 (15)
6OPRI 38 103 25 (24)
7OPRI 1 3 0 (0)
9OPRI 1 1 1 (100)
P102L 34 133 32 (24)
P105L 1 2 2 (100)
A117V 16 60 5 (8)
Y163X 4 9 2 (22)
D178N 7 25 6 (24)
E200K 15 78 24 (31)
V210I 2 11 1 (9)
E211Q 1 0 0 (0)
Q212P 1 4 2 (50)
Total 135 460 104 (23)
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Table 2
Gender comparison in prion protein gene predictive testing: the proportion of eligible first degree relatives, for 
each sex separately, who have undergone predictive testing for a PRNP gene mutation. There was no gender 
imbalance (P=0.18; Fisher’s exact test).
Mutation Proportion tested of
eligible female first
degree relatives (%)
Proportion tested of
eligible male first degree
relatives (%)
G54S 0/1 (0) 0/1 (0)
4OPRI 0/4 (0) 1/5 (20)
5OPRI 2/11 (18) 1/9 (11)
6OPRI 10/48 (21) 15/55 (27)
7OPRI 0/2 (0) 0/1 (0)
9OPRI 1/1 (100) 0/0 (0)
P102L 13/66 (20) 19/67 (28)
P105L 1/1 (100) 1/1 (100)
A117V 5/37 (14) 0/23 (0)
Y163X 2/7 (29) 0/2 (0)
D178N 4/15 (27) 2/10 (20)
E200K 8/37 (22) 16/41 (39)
V210I 0/4 (0) 1/7 (14)
E211Q 0/0 (0) 0/0 (0)
Q212P 1/2 (50) 1/2 (50)
Total 47/236 (20) 57/224 (25)
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